SAI LIFE SCIENCES LTD (SAILIFE) fair value: what the stock is really worth
As of Oct 1, 2026: fair value of SAI LIFE SCIENCES LTD ₹361, price ₹1,541, upside -76.6%, quality 49 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch SAI LIFE SCIENCES LTD for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 1, 2026.
How to read this chart
21‑month range ₹640.25 – ₹1,675 · fair‑value band ₹270.33 – ₹451.70 · the ₹1,541 price screens above the ₹361.36 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 1, 2026.
Follow SAI LIFE SCIENCES in your weekly email
Every Wednesday you see whether SAI LIFE SCIENCES is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Sai Life Sciences Limited operates as a contract research, development, and manufacturing organization (CRDMO) in India and internationally. It provides medicinal chemistry, pharmacokinetics, manufacturing, and contract development services.
Show more
Sai Life Sciences Limited operates as a contract research, development, and manufacturing organization (CRDMO) in India and internationally. It provides medicinal chemistry, pharmacokinetics, manufacturing, and contract development services. The company was formerly known as SAI Advantium Pharma Limited and changed its name to Sai Life Sciences Limited in July 2006. Sai Life Sciences Limited was incorporated in 1999 and is based in Hyderabad, India.
Stock analysis
SAI LIFE SCIENCES LTD (SAILIFE) currently trades at ₹1,541, while our model-based Fair Value estimate is ₹361.36, 76.6% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of ₹512.94 per share, and 0 of the 14 models we run sit above the ₹1,541 price.
Bear case: the Asset-Based group reads lowest at ₹78.34, and 14 of the 14 models stay below the price. Evidence for this calculation is medium.
Scenario range: ₹270.33 (bear) to ₹451.70 (bull), the price of ₹1,541 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 49/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
SAI LIFE SCIENCES LTD reported revenue of ₹21.9B in FY2026 versus ₹8.7B in FY2022, a compound +26.0%/yr. Reported net income was ₹3.5B in FY2026, compounding +173.6%/yr from FY2022. FY2022 was a trough year, so the rate overstates the trend.
Key figures
Market cap ₹327B (≈ $3.4B) · P/E ratio 90.4 · P/S ratio 14.4 · EPS (TTM) ₹17.04 · Net margin 15.9% · Return on equity 15.1% · Return on assets (EBIT) 6.9% · Operating margin 18.4%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades about 8% below its 52-week high and 94% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −6% fair-value upside, at −77%, SAILIFE screens richer than that median.
Fair Value models
The price assumes far more growth than our models allow for, so the models scatter widely (₹78.34 to ₹778.94). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear ₹270.33Fair Value ₹361.36Bull ₹451.70
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2026 figures (about 6 months old). Earnings retained since then (₹8.64 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+29.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+22.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+23.6%
Start year 2021 (pandemic)
’21
’22
’23
’24
’25
’26
What shareholders gained per year (last 5 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
≈ +53.6%
Earnings growth per share plus dividend.
Earnings per share, growth per year+53.6%
Dividend (yield on the price)0.0%
Profit margin 2022 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.4% → 21%
⚠ Approximate: the rate leans on 2026, which sits 313% above its own trend.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 135 stocks
Beats the industry median on 6/12 measures
A mixed picture versus its industry peers.
Valuation
Quality Score49 · Below median
Fair Value upside−76.6% · Bottom 25%
Profitability
Return on equity (TTM)15.1% · Top 25%
Return on assets8.6% · Top 25%
Net margin (TTM)16.1% · Top 25%
Operating margin (TTM)18.4% · Top 25%
Growth and dividend
Revenue growth11.7% · Above median
Balance sheet
Debt / equity0.01× · Below median
Valuation Multiplesvs Diagnostics & Research median · lower = cheaper
P/E (TTM)90.4× · Priciest 25%
P/B13.18× · Priciest 25%
P/S (TTM)14.54× · Priciest 25%
EV/EBITDA48.8× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)59· sector 28
PAST (return on equity)61· sector 10
HEALTH (low debt)100· sector 93
DIVIDEND (yield)0· sector 30
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "SAI LIFE SCIENCES LTD Fair Value". https://www.fairvalue-calculator.com/stock/SAILIFE
Frequently asked questions
Is SAI LIFE SCIENCES LTD (SAILIFE) overvalued or undervalued?
As of Oct 1, 2026, our model estimates a fair value of ₹361.36 versus a price of ₹1,541, about −77% upside (overvalued).
What is the fair value of SAILIFE?
Our model-based fair value for SAI LIFE SCIENCES LTD is ₹361.36 (as of Oct 1, 2026), built from audited fundamentals. The current price: ₹1,541.
What is the quality score of SAILIFE?
SAI LIFE SCIENCES LTD has a Quality Score of 49/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for SAI LIFE SCIENCES LTD (SAILIFE)?
Our model-based price target is the fair value of ₹361.36 (as of Oct 1, 2026) from 14 valuation models. Cautious scenario ₹270.33, optimistic scenario ₹451.70. It is a calculation from audited fundamentals, not an analyst target.
What is the SAI LIFE SCIENCES LTD stock forecast for 2026?
Our models put fair value at ₹361.36, about −77% upside versus a price of ₹1,541 (overvalued). Cautious scenario ₹270.33, optimistic scenario ₹451.70. The calculation is refreshed regularly with new filings.
What is the revenue of SAI LIFE SCIENCES LTD (SAILIFE)?
SAI LIFE SCIENCES LTD reported trailing-twelve-month revenue of about ₹22.5B (latest available figure, as of Oct 1, 2026).
What is the intrinsic value of SAI LIFE SCIENCES LTD (SAILIFE)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For SAI LIFE SCIENCES LTD it is ₹361.36 per share (as of Oct 1, 2026), against a price of ₹1,541. It is the blended result of 14 valuation models (cash flow, earnings, asset, dividend).
Is SAI LIFE SCIENCES LTD stock overvalued or undervalued in 2026?
As of Oct 1, 2026, SAILIFE trades above its calculated fair value: price ₹1,541, fair value ₹361.36, a gap of about −77% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SAILIFE?
No. The price is what the market pays today (₹1,541); the fair value is what the company's own numbers justify (₹361.36). For SAI LIFE SCIENCES LTD the two are ₹1,180 per share apart. That gap is exactly why we show both numbers side by side.
How much is SAI LIFE SCIENCES LTD worth?
The market values SAI LIFE SCIENCES LTD at about ₹327B (market capitalisation, as of Oct 1, 2026). Per share that is ₹1,541; our models calculate a fair value of ₹361.36 per share.
What do the bullish and bearish scenarios say about SAILIFE?
Our models span a range for SAI LIFE SCIENCES LTD: cautious scenario ₹270.33, base ₹361.36, optimistic ₹451.70 per share (as of Oct 1, 2026, price ₹1,541). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of SAILIFE?
SAI LIFE SCIENCES LTD trades at a price-to-earnings ratio of 90.4 (as of Oct 1, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹361.36 is built from several models across several years. Other multiples: P/B 13.2, P/S 14.5, EV/EBITDA 48.8.
How solid is the balance sheet of SAI LIFE SCIENCES LTD (SAILIFE)?
Balance-sheet figures for SAI LIFE SCIENCES LTD (as of Oct 1, 2026): return on equity 15.1%, debt of 0.01 per unit of equity. They feed the Quality Score of 49/100, which measures business quality independently of the share price.
How far is SAILIFE from its 52-week high?
SAI LIFE SCIENCES LTD trades at ₹1,541, about 8% below its 52-week high of ₹1,675 and 94% above the low of ₹795.00 (as of Oct 1, 2026). Distance from the high says nothing about value: that is what the fair value of ₹361.36 is for.
Which stocks are comparable to SAI LIFE SCIENCES LTD?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Agilent Technologies, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is SAI LIFE SCIENCES LTD stock attractive at the current price?
The data as of Oct 1, 2026: price ₹1,541, calculated fair value ₹361.36 (−77%), Quality Score 49/100, from 14 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of SAILIFE calculated?
We run SAI LIFE SCIENCES LTD through 14 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹361.36, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. SAI LIFE SCIENCES LTD itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of SAI LIFE SCIENCES LTD (SAILIFE)?
The closing price on Oct 1, 2026 was ₹1,541. Our model-based fair value is ₹361.36, about −77% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with SAI LIFE SCIENCES LTD right now?
The price sits above even our optimistic bull case (₹451.70). The favourable scenario is already priced in. Solid but not exceptional quality (49/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of SAI LIFE SCIENCES LTD
How large is the market capitalisation of SAI LIFE SCIENCES LTD (SAILIFE)?
The market capitalisation of SAI LIFE SCIENCES LTD is ₹327B (≈ $3.4B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of SAI LIFE SCIENCES LTD (SAILIFE)?
The price-to-sales ratio of SAI LIFE SCIENCES LTD is 14.4 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of SAI LIFE SCIENCES LTD (SAILIFE)?
Earnings per share at SAI LIFE SCIENCES LTD are ₹17.04 (price ÷ EPS = P/E 90.4). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of SAI LIFE SCIENCES LTD (SAILIFE)?
The net margin of SAI LIFE SCIENCES LTD is 15.9% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of SAI LIFE SCIENCES LTD (SAILIFE)?
The return on equity (ROE) of SAI LIFE SCIENCES LTD is 15.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of SAI LIFE SCIENCES LTD (SAILIFE)?
On an EBIT basis the return on assets of SAI LIFE SCIENCES LTD is 6.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of SAI LIFE SCIENCES LTD (SAILIFE)?
The operating margin of SAI LIFE SCIENCES LTD is 18.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at SAI LIFE SCIENCES LTD (SAILIFE)?
Revenue at SAI LIFE SCIENCES LTD is growing +11.7% versus a year earlier (3y avg +22.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at SAI LIFE SCIENCES LTD (SAILIFE)?
Earnings per share at SAI LIFE SCIENCES LTD are growing +20.8% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does SAI LIFE SCIENCES LTD (SAILIFE) generate?
The free cash flow of SAI LIFE SCIENCES LTD is −₹721M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does SAI LIFE SCIENCES LTD (SAILIFE) carry?
The net debt of SAI LIFE SCIENCES LTD is ₹1.8B (fiscal year 2026). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch SAI LIFE SCIENCES LTD in the live analysis
One click puts SAI LIFE SCIENCES LTD on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
